Показать сокращенную информацию
dc.contributor.author | Chang T.C. | |
dc.contributor.author | Vong K. | |
dc.contributor.author | Yamamoto T. | |
dc.contributor.author | Tanaka K. | |
dc.date.accessioned | 2022-02-09T20:37:10Z | |
dc.date.available | 2022-02-09T20:37:10Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1433-7851 | |
dc.identifier.uri | https://dspace.kpfu.ru/xmlui/handle/net/169410 | |
dc.description.abstract | An emerging approach in the field of targeted drug delivery is the establishment of abiotic metal-triggered prodrug mechanisms that can control the release of bioactive drugs. Currently, the design of prodrugs that use abiotic metals as a trigger relies heavily on uncaging strategies. Here, we introduce a strategy based on the gold-catalyzed activation of a phenanthridinium-based prodrug via hydroamination under physiological conditions. To make the prodrug strategy biocompatible, a gold artificial metalloenzyme (ArM) based on human serum albumin, rather than the free gold metal complex, was used as a trigger for prodrug activation. The albumin-based gold ArM protected the catalytic activity of the bound gold metal even in the presence of up to 1 mM glutathione in vitro. The drug synthesized via the gold ArM exerted a therapeutic effect in cell-based assays, highlighting the potential usefulness of the gold ArM in anticancer applications. | |
dc.relation.ispartofseries | Angewandte Chemie - International Edition | |
dc.subject | antitumor agents | |
dc.subject | gold catalysts | |
dc.subject | metalloenzymes | |
dc.subject | phenanthridinium | |
dc.subject | prodrugs | |
dc.title | Prodrug Activation by Gold Artificial Metalloenzyme-Catalyzed Synthesis of Phenanthridinium Derivatives via Hydroamination | |
dc.type | Article | |
dc.relation.ispartofseries-issue | 22 | |
dc.relation.ispartofseries-volume | 60 | |
dc.collection | Публикации сотрудников КФУ | |
dc.relation.startpage | 12446 | |
dc.source.id | SCOPUS14337851-2021-60-22-SID85103562650 |